基线心脏冲击严重程度对使用Impella治疗患者的结果的影响
Hiroaki Yokoyama1,2, Shinobu Hosokawa1, Masataka Sata2
1Department of Cardiology Tokushima Red Cross Hospital Tokushima Japan.
Journal of the American Heart Association
|August 23, 2025
概括
心血管血管和干预学会的冲击阶段系统有效地预测了高级心血管冲击 (CS) 阶段D和E的医院死亡. 然而,它的准确性在早期的CS阶段是有限的,这表明需要改进风险分层工具.
科学领域:
- 心脏病学
- 危急护理医学
- 医疗服务研究
背景情况:
- 对于心脏性休克患者来说,风险分层至关重要.
- 心血管血管图谱与干预协会 (SCAI) 的冲击阶段系统由CS工作组改进.
- 评估SCAI系统在亚洲人群中的实用性对于了解医院内不良事件很重要.
研究的目的:
- 评估精制的SCAI冲击分期系统在亚洲人口中的有用性.
- 研究SCAI冲击阶段与住院不良事件,特别是死亡率之间的关联.
- 确定分期系统是否准确地预测CS不同严重程度的结果.
主要方法:
- 采用了来自日本全国民用Impella器件在CS患者使用的数据.
- 包括在2020年2月至2023年12月期间获得Impella支持的患者.
- 将患者分配到SCAI阶段 (B,C,D,E) 并分析住院死亡率,使用B阶段作为参考,并进行混调整.
主要成果:
- 分析了4643名CS患者 (中位数年龄69岁,女性为23. 3%).
- 在调整后,D和E阶段的住院死亡率明显较高 (D的OR2. 41,P< 0. 001;E的OR4. 90,P< 0. 001).
- 与B阶段相比,C阶段的住院死亡没有显著差异 (OR1.12,P=0. 653).
结论:
- 经过改进的SCAI分期系统显示,在更晚期 (D和E) 的住院死亡与死亡有令人满意的关联.
- 该系统在CS早期阶段 (C阶段) 的预测能力较低.
- 需要进一步的研究来开发更准确和更全面的心脏性休克分期系统.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
47
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
47
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75